Knight Therapeutics Inc KHTRF

Endo watch ...

[MrMugsy]

Endo is still a long way from solving its Opioid litigations - and - in selling off assets.

By latest count, the Paladin asset base has dropped from 69 drugs (at peak) to 54 drugs (now) - about a 22% reduction in the base drug count.

No idea what percentage of sales that represents but I'm assuming the revenue portion equates to more than 22% of total sales.

Paladin is getting smaller - less valuable.  Surely further licenses will not be renewed here as the fate of Endo hangs in the balance.

Even if Endo wanted to sell the division - the court likely wouldn't allow it as Opioid litigation likely puts a stop to that.

Further erosion and loss in value for Paladin products - likely in the cards.

[Chianchin]

GUD and Endo can learn from eachothers how to keep losing more fortunes with old generics drugs. Much worst for GUD in burnig fires, inflation  and leftist revolutions  in latam

[curiousj]

do you how much of that 15 drugs drop at Paladin was relicensed to Knight? 

[Chianchin]

None, zero, nada

[MrMugsy]

No - sorry - I don't know. I'm not sure if those 15 drugs actually left Endo or if they were just moved to different portfolio or a combination of the two. I know "Plan B" was one of the drugs ... that's the one I was looking for - then realized many others were missing in the portfolio (based on the old count of 69). I'm investigating "Plan B" to see where it

[Chianchin]

$5.11 today, soon and slowly breaching below $5 and than all hell will brake loose. One short seller senses that the propping buy back is over the party starts. I will be a buyer at $2